225 related articles for article (PubMed ID: 1998982)
1. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Grunewald R; Kantarjian H; Du M; Faucher K; Tarassoff P; Plunkett W
J Clin Oncol; 1992 Mar; 10(3):406-13. PubMed ID: 1740680
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
5. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
6. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
7. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
[TBL] [Abstract][Full Text] [Related]
8. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
10. A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
Nishi R; Yamauchi T; Ueda T
Cancer Sci; 2006 Nov; 97(11):1274-8. PubMed ID: 17034368
[TBL] [Abstract][Full Text] [Related]
11. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
12. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
[TBL] [Abstract][Full Text] [Related]
14. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
[TBL] [Abstract][Full Text] [Related]
16. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
19. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
20. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]